Search

Karen J Devcich

from Mettawa, IL
Age ~68
Get Report
Also known as:
Karen C Devcich, Karen Devcich Revocable, Jane Devcich, Karen J Steven, Karen J Devcic, Christin Devcich, Karen A
Related to:
Donald T Devcich, 68Bryan M Devcich, 60Steven J Devcich, 70Patrick M Devcich, 62Steven R Devcich, 37Helen M Devcich, 99Christin M Devcich, 34
Connected to:
Lavanya Devdas, 45Soumendra Devdas, 50Michael T Deveans, 69Anne M Deveau, 90Brett A Deveau, 50Camila Deveau, 42Carol Deveau, 80Cynthia J Deveau, 61Debra A Deveau, 63

Karen Devcich Phones & Addresses

  • Mettawa, IL
  • Lisle, IL
  • 480 Muirfield Ln, Deerfield, IL 60015 (847) 374-0656 (847) 374-0658 (847) 948-8166
  • Riverwoods, IL

Publications

Us Patents

Extended Release Formulations Of Erythromycin Derivatives

View page
US Patent:
6872407, Mar 29, 2005
Filed:
Nov 22, 2002
Appl. No.:
10/302166
Inventors:
Gerard F. Notario - Chicago IL, US
Robert N. Palmer - Gurnee IL, US
Richard C. Hom - Wilmette IL, US
Jie Zhang - Basking Ridge NJ, US
Karen J. Devcich - Grayslake IL, US
Susan J. Semla - Evanston IL, US
Assignee:
Abbott Laboratories - Abbott Park IL
International Classification:
A61K009/20
A61K009/22
A61K009/36
US Classification:
424464, 424468, 424480
Abstract:
Disclosed is a pharmaceutical composition for extended release of an erythromycin derivative in the gastrointestinal environment. The composition comprises an erythromycin derivative and a pharmaceutically acceptable polymer so that, when ingested orally, the composition induces statistically significantly lower Cin the plasma than an immediate release composition of the erythromycin derivative while maintaining bioavailability and minimum concentration substantially equivalent to that of the immediate release composition of the erythromycin derivative upon multiple dosing. The compositions of the invention have an improved taste profile and reduced gastrointestinal side effects as compared to those for the immediate release composition.

Extended Release Formulations Of Erythromycin Derivatives

View page
US Patent:
20050064033, Mar 24, 2005
Filed:
Nov 5, 2004
Appl. No.:
10/983177
Inventors:
Gerard Notario - Chicago IL, US
Robert Palmer - Gurnee IL, US
Richard Hom - Wilmette IL, US
Jie Zhang - Basking Ridge NJ, US
Karen Devcich - Grayslake IL, US
Susan Semla - Evanston IL, US
International Classification:
A61K009/22
A61K031/7048
US Classification:
424468000, 514029000
Abstract:
Disclosed is a pharmaceutical composition for extended release of an erythromycin derivative in the gastrointestinal environment. The composition comprises an erythromycin derivative and a pharmaceutically acceptable polymer so that, when ingested orally, the composition induces statistically significantly lower Cmax in the plasma than an immediate release composition of the erythromycin derivative while maintaining bioavailability and minimum concentration substantially equivalent to that of the immediate release composition of the erythromycin derivative upon multiple dosing. The compositions of the invention have an improved taste profile and reduced gastrointestinal side effects as compared to those for the immediate release composition.

Extended Release Formulations Of Erythromycin Derivatives

View page
US Patent:
20060039969, Feb 23, 2006
Filed:
Mar 28, 2005
Appl. No.:
11/091637
Inventors:
Gerard Notario - Chicago IL, US
Robert Palmer - Gurnee IL, US
Richard Hom - Wilmette IL, US
Jie Zhang - Basking Ridge NJ, US
Karen Devcich - Grayslake IL, US
Susan Semla - Evanston IL, US
International Classification:
A61K 9/20
A61K 31/7048
US Classification:
424464000, 514029000
Abstract:
Disclosed is a pharmaceutical composition for extended release of an erythromycin derivative in the gastrointestinal environment. The composition comprises an erythromycin derivative and a pharmaceutically acceptable polymer so that, when ingested orally, the composition induces statistically significantly lower Cin the plasma than an immediate release composition of the erythromycin derivative while maintaining bioavailability and minimum concentration substantially equivalent to that of the immediate release composition of the erythromycin derivative upon multiple dosing. The compositions of the invention have an improved taste profile and reduced gastrointestinal side effects as compared to those for the immediate release composition.

Extended Release Formulations Of Erythromycin Derivatives

View page
US Patent:
6551616, Apr 22, 2003
Filed:
Oct 13, 1999
Appl. No.:
09/416916
Inventors:
Gerard F. Notario - Chicago IL
Robert N. Palmer - Gurnee IL
Richard C. Hom - Wilmette IL
Jie Zhang - Basking Ridge NJ
Karen J. Devcich - Grayslake IL
Susan J. Semla - Evanston IL
Assignee:
Abbott Laboratories - Abbott Park IL
International Classification:
A61K 920
US Classification:
424464, 424468, 424480
Abstract:
Disclosed is a pharmaceutical composition for extended release of an erythromycin derivative in the gastrointestinal environment. The composition comprises an erythromycin derivative and a pharmaceutically acceptable polymer so that, when ingested orally, the composition induces statistically significantly lower C in the plasma than an immediate release composition of the erythromycin derivative while maintaining bioavailability and minimum concentration substantially equivalent to that of the immediate release composition of the erythromycin derivative upon multiple dosing. The compositions of the invention have an improved taste profile and reduced gastrointestinal side effects as compared to those for the immediate release composition.
Control profile
Karen J Devcich from Mettawa, IL, age ~68 Get Report